Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Apatinib maintenance in platinum-sensitive relapsed ovarian cancer
NCT06081595Phase 2Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC). Primary endpoint: Progression Free Survival up to 2 years. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06081595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081595.